Free Trial
ASX:AC8

AusCann Group (AC8) Stock Price, News & Analysis

About AusCann Group Stock (ASX:AC8)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
537,446 shs
Average Volume
N/A
Market Capitalization
$17.62 million
P/E Ratio
N/A
Dividend Yield
6.79%
Price Target
N/A
Consensus Rating
N/A

Company Overview

AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. AusCann Group Holdings Ltd is based in West Perth, Australia.

Receive AC8 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AusCann Group and its competitors with MarketBeat's FREE daily newsletter.

AC8 Stock News Headlines

AusCann Group Holdings Ltd (ACNNF)
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
AC8.AX - AusCann Group Holdings Ltd
ACNNF AusCann Group Holdings Ltd
See More Headlines

AC8 Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that AusCann Group investors own include 3D Systems (DDD), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Workday (WDAY), Zoom Video Communications (ZM), Zynerba Pharmaceuticals (ZYNE) and Ambarella (AMBA).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
ASX:AC8
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.36 million
Price / Cash Flow
2.05
Book Value
A$0.01 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$17.62 million
Optionable
Not Optionable
Beta
0.72
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (ASX:AC8) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners